DE60336225D1 - Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend - Google Patents

Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend

Info

Publication number
DE60336225D1
DE60336225D1 DE60336225T DE60336225T DE60336225D1 DE 60336225 D1 DE60336225 D1 DE 60336225D1 DE 60336225 T DE60336225 T DE 60336225T DE 60336225 T DE60336225 T DE 60336225T DE 60336225 D1 DE60336225 D1 DE 60336225D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
polymorph
fliberserine
new pharmaceutical
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60336225T
Other languages
English (en)
Inventor
Thomas Friedl
Guido Bernhard Radtke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Application granted granted Critical
Publication of DE60336225D1 publication Critical patent/DE60336225D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60336225T 2002-05-22 2003-05-19 Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend Expired - Lifetime DE60336225D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02011224 2002-05-22
PCT/EP2003/005226 WO2003097058A1 (en) 2002-05-22 2003-05-19 New pharmaceutical compositions containing flibanserin polymorph a

Publications (1)

Publication Number Publication Date
DE60336225D1 true DE60336225D1 (de) 2011-04-14

Family

ID=29433081

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60336225T Expired - Lifetime DE60336225D1 (de) 2002-05-22 2003-05-19 Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend

Country Status (25)

Country Link
EP (1) EP1511489B1 (de)
JP (1) JP3919788B2 (de)
KR (1) KR101054237B1 (de)
CN (3) CN1655789A (de)
AT (1) ATE499939T1 (de)
BR (1) BRPI0311189B8 (de)
CA (1) CA2483597C (de)
CY (1) CY1111470T1 (de)
DE (1) DE60336225D1 (de)
DK (1) DK1511489T3 (de)
EA (1) EA007185B1 (de)
EC (1) ECSP045493A (de)
ES (1) ES2361994T3 (de)
HR (1) HRP20041092B1 (de)
IL (1) IL164440A0 (de)
ME (1) MEP55308A (de)
MX (1) MXPA04011487A (de)
NO (1) NO329414B1 (de)
NZ (1) NZ537253A (de)
PL (1) PL211062B1 (de)
RS (1) RS51718B (de)
SI (1) SI1511489T1 (de)
UA (1) UA80135C2 (de)
WO (1) WO2003097058A1 (de)
ZA (1) ZA200408151B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2608713A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EP2056797A2 (de) 2006-08-25 2009-05-13 Boehringer Ingelheim International GmbH System mit kontrollierter freisetzung und verfahren zu seiner herstellung
JP2010513390A (ja) 2006-12-20 2010-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 混合セロトニン受容体親和性を有する硫酸化ベンズイミダゾロン誘導体
EP1955699A1 (de) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Verwendung von Flibanserin zur Behandlung von Schlaflosigkeit
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2090297A1 (de) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulierungen aus Flibanserin
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
CN113683570A (zh) * 2016-01-31 2021-11-23 孟晓明 氟班色林的新晶型及其制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
AU2002331361B2 (en) * 2001-08-02 2008-06-05 Sprout Pharmaceuticals, Inc. Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung

Also Published As

Publication number Publication date
NO20044547L (no) 2004-12-17
IL164440A0 (en) 2005-12-18
UA80135C2 (en) 2007-08-27
CY1111470T1 (el) 2015-08-05
JP2005530787A (ja) 2005-10-13
ECSP045493A (es) 2005-03-10
PL372457A1 (en) 2005-07-25
BRPI0311189B8 (pt) 2021-05-25
EA200401515A1 (ru) 2005-06-30
EA007185B1 (ru) 2006-08-25
CN1655789A (zh) 2005-08-17
WO2003097058A1 (en) 2003-11-27
CA2483597A1 (en) 2003-11-27
CN102240289A (zh) 2011-11-16
KR101054237B1 (ko) 2011-08-08
HRP20041092A2 (en) 2005-06-30
BR0311189A (pt) 2005-02-22
KR20040111668A (ko) 2004-12-31
JP3919788B2 (ja) 2007-05-30
ZA200408151B (en) 2006-06-28
RS98704A (en) 2006-12-15
MEP55308A (en) 2011-05-10
BRPI0311189B1 (pt) 2019-04-09
ES2361994T3 (es) 2011-06-27
HRP20041092B1 (hr) 2013-05-31
ATE499939T1 (de) 2011-03-15
CA2483597C (en) 2010-02-09
CN101002780A (zh) 2007-07-25
AU2003240672A1 (en) 2003-12-02
PL211062B1 (pl) 2012-04-30
DK1511489T3 (da) 2011-05-02
SI1511489T1 (sl) 2011-06-30
NO329414B1 (no) 2010-10-18
RS51718B (en) 2011-10-31
NZ537253A (en) 2007-09-28
EP1511489A1 (de) 2005-03-09
MXPA04011487A (es) 2005-02-14
EP1511489B1 (de) 2011-03-02

Similar Documents

Publication Publication Date Title
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
BR0015188A (pt) Composições farmacêuticas
NO20063429L (no) Brusende oral opiat doseringsform
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
UA96449C2 (en) Stable laquinimod preparations
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
ATE303149T1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
DE60317803D1 (de) Pharmazeutische zusammensetzungen enthaltend cyclosporin zur oralen verabreichung
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
NO20064808L (no) Orale matrixformuleringer med licarbazepin
TW200509992A (en) Dosage form containing pantoprazole as active ingredient
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
TW200503783A (en) Oral pharmaceutical preparation for proton pump antagonists
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
SE0203817D0 (sv) New composition
ATE261732T1 (de) Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl
UA87152C2 (ru) Твердая фармацевтическая композиция, содержащая миртазапин, и способ ее получения
TW200633717A (en) Process for and intermediates in the preparation of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents
DK1399143T3 (da) Anvendelsen af Acetyl L-carnitin til fremstilling af et lægemiddel til behandling af anhedoni
TNSN06299A1 (en) Oral matrix formulations comprising licarbazepine
ATE429905T1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung